DiabetesDiabetes Mellitus, Type 2Medullary Thyroid CarcinomaWeight Management
Investigational drug(s) / intervention(s)
No treatment given
No treatment given: None. Non-interventional study.
Study summary
This study is conducted in the United States of America (USA). The aim of the study is to monitor the number of annual new adult cases of medullary thyroid carcinoma (MTC) and to establish a registry for these new cases in order to identify any possible increase related to the introduction of liraglutide, exenatide once-weekly, and other GLP-1 receptor agonists into the US market.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* A record of medullary thyroid carcinoma (MTC) identified from state/regional population-based cancer registries
* At least 18 years or older.
There are no other inclusion or exclusion criteria.
Primary outcome measure(s)
Annual incidence of MTC in the US to identify any possible increase related to the introduction of liraglutide, exenatide once-weekly, and other GLP-1 receptor agonists into the US market. — Up to 15 years
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.